Merck Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Funding
• Alerts
• Clinical Trials
• Forums

Berzosertib Human Mass Balance Study (DDRiver Solid Tumors 208)
Condition:   Advanced Solid Tumor Interventions:   Drug: [14C]M6620;   Drug: M6620;   Drug: Topotecan Sponsor:   Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 18, 2022 Category: Research Source Type: clinical trials

Study Comparing Pharmacokinetics of Different Formulations of Evobrutinib in Healthy Participants
Condition:   Healthy Interventions:   Drug: Ref (TF2);   Drug: Evobrutinib MR-T1;   Drug: Evobrutinib MR-T2;   Drug: Evobrutinib MR-T3;   Drug: Evobrutinib MR-T4;   Drug: Evobrutinib MUPS-C1;   Drug: Evobrutinib MUPS-C2;   Drug: Evobrutinib MUPS-C3;   Drug: Evobrutinib MUPS-C4 Sponsors:   Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany;   Merck KGaA, Darmstadt, Germany Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 18, 2022 Category: Research Source Type: clinical trials

Berzosertib Human Mass Balance Study (DDRiver Solid Tumors 208)
Condition:   Advanced Solid Tumor Interventions:   Drug: [14C]M6620;   Drug: M6620;   Drug: Topotecan Sponsor:   Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 18, 2022 Category: Research Source Type: clinical trials

Study Comparing Pharmacokinetics of Different Formulations of Evobrutinib in Healthy Participants
Condition:   Healthy Interventions:   Drug: Ref (TF2);   Drug: Evobrutinib MR-T1;   Drug: Evobrutinib MR-T2;   Drug: Evobrutinib MR-T3;   Drug: Evobrutinib MR-T4;   Drug: Evobrutinib MUPS-C1;   Drug: Evobrutinib MUPS-C2;   Drug: Evobrutinib MUPS-C3;   Drug: Evobrutinib MUPS-C4 Sponsors:   Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany;   Merck KGaA, Darmstadt, Germany Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 18, 2022 Category: Research Source Type: clinical trials

Berzosertib Human Mass Balance Study (DDRiver Solid Tumors 208)
Condition:   Advanced Solid Tumor Interventions:   Drug: [14C]M6620;   Drug: M6620;   Drug: Topotecan Sponsor:   Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 18, 2022 Category: Research Source Type: clinical trials

Study Comparing Pharmacokinetics of Different Formulations of Evobrutinib in Healthy Participants
Condition:   Healthy Interventions:   Drug: Ref (TF2);   Drug: Evobrutinib MR-T1;   Drug: Evobrutinib MR-T2;   Drug: Evobrutinib MR-T3;   Drug: Evobrutinib MR-T4;   Drug: Evobrutinib MUPS-C1;   Drug: Evobrutinib MUPS-C2;   Drug: Evobrutinib MUPS-C3;   Drug: Evobrutinib MUPS-C4 Sponsors:   Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany;   Merck KGaA, Darmstadt, Germany Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 18, 2022 Category: Research Source Type: clinical trials

Berzosertib Human Mass Balance Study (DDRiver Solid Tumors 208)
Condition:   Advanced Solid Tumor Interventions:   Drug: [14C]M6620;   Drug: M6620;   Drug: Topotecan Sponsor:   Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 18, 2022 Category: Research Source Type: clinical trials

Study Comparing Pharmacokinetics of Different Formulations of Evobrutinib in Healthy Participants
Condition:   Healthy Interventions:   Drug: Ref (TF2);   Drug: Evobrutinib MR-T1;   Drug: Evobrutinib MR-T2;   Drug: Evobrutinib MR-T3;   Drug: Evobrutinib MR-T4;   Drug: Evobrutinib MUPS-C1;   Drug: Evobrutinib MUPS-C2;   Drug: Evobrutinib MUPS-C3;   Drug: Evobrutinib MUPS-C4 Sponsors:   Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany;   Merck KGaA, Darmstadt, Germany Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 18, 2022 Category: Research Source Type: clinical trials

Berzosertib Human Mass Balance Study (DDRiver Solid Tumors 208)
Condition:   Advanced Solid Tumor Interventions:   Drug: [14C]M6620;   Drug: M6620;   Drug: Topotecan Sponsor:   Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 18, 2022 Category: Research Source Type: clinical trials

Study Comparing Pharmacokinetics of Different Formulations of Evobrutinib in Healthy Participants
Condition:   Healthy Interventions:   Drug: Ref (TF2);   Drug: Evobrutinib MR-T1;   Drug: Evobrutinib MR-T2;   Drug: Evobrutinib MR-T3;   Drug: Evobrutinib MR-T4;   Drug: Evobrutinib MUPS-C1;   Drug: Evobrutinib MUPS-C2;   Drug: Evobrutinib MUPS-C3;   Drug: Evobrutinib MUPS-C4 Sponsors:   Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany;   Merck KGaA, Darmstadt, Germany Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 18, 2022 Category: Research Source Type: clinical trials

Berzosertib Human Mass Balance Study (DDRiver Solid Tumors 208)
Condition:   Advanced Solid Tumor Interventions:   Drug: [14C]M6620;   Drug: M6620;   Drug: Topotecan Sponsor:   Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 18, 2022 Category: Research Source Type: clinical trials

Study Comparing Pharmacokinetics of Different Formulations of Evobrutinib in Healthy Participants
Condition:   Healthy Interventions:   Drug: Ref (TF2);   Drug: Evobrutinib MR-T1;   Drug: Evobrutinib MR-T2;   Drug: Evobrutinib MR-T3;   Drug: Evobrutinib MR-T4;   Drug: Evobrutinib MUPS-C1;   Drug: Evobrutinib MUPS-C2;   Drug: Evobrutinib MUPS-C3;   Drug: Evobrutinib MUPS-C4 Sponsors:   Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany;   Merck KGaA, Darmstadt, Germany Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 18, 2022 Category: Research Source Type: clinical trials

Berzosertib Human Mass Balance Study (DDRiver Solid Tumors 208)
Condition:   Advanced Solid Tumor Interventions:   Drug: [14C]M6620;   Drug: M6620;   Drug: Topotecan Sponsor:   Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 18, 2022 Category: Research Source Type: clinical trials

Study Comparing Pharmacokinetics of Different Formulations of Evobrutinib in Healthy Participants
Condition:   Healthy Interventions:   Drug: Ref (TF2);   Drug: Evobrutinib MR-T1;   Drug: Evobrutinib MR-T2;   Drug: Evobrutinib MR-T3;   Drug: Evobrutinib MR-T4;   Drug: Evobrutinib MUPS-C1;   Drug: Evobrutinib MUPS-C2;   Drug: Evobrutinib MUPS-C3;   Drug: Evobrutinib MUPS-C4 Sponsors:   Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany;   Merck KGaA, Darmstadt, Germany Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 18, 2022 Category: Research Source Type: clinical trials

Merck and Ridgeback ’s Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, Demonstrated Activity Against Omicron Variant in In Vitro Studies
KENILWORTH, N.J.& MIAMI--(BUSINESS WIRE) January 28, 2022 -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced data from six preclinical studies demonstrating that molnupiravir,... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 28, 2022 Category: Pharmaceuticals Source Type: clinical trials